{"disease":{"id":"pulmonary-arterial-hypertension-pah-who-group-1-pulmonary-hypertension","name":"pulmonary arterial hypertension pah who group 1 pulmonary hypertension"},"drugs":{"marketed":[{"drug_id":"sotatercept","indication_name":"pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Winrevair","generic_name":"SOTATERCEPT","company_name":"Merck Sharp Dohme","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":"1443","mechanism":"Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07217522","title":"Rutgers University Study of the Genetics of Pulmonary Hypertension","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}